Zydus Gets Final USFDA Nod for Doxycycline Hyclate Capsules | CORPORATE ETHOS

Zydus Gets Final USFDA Nod for Doxycycline Hyclate Capsules

By: | June 2, 2018
Zydus-Cadila

Jun 2: Drug manufacturing major Zydus Cadila on Saturday said that it has received the final approval from the USFDA to market its Doxycycline Hyclate Capsules USP, 50 mg and 100 mg. It is a tetracycline antibiotic used for treatment of a wide variety of bacterial infections, including those that cause acne.

“This medication is also used for prophylaxis of malaria. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad,” the company said.

Based in Ahmedabad, the Pankaj R Patel promoted Zydus Cadila Group is a research driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.

The group now has more than 195 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.